Karam Mounzer

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Kenneth H. Mayer, Jean‐Michel Molina, Melanie Thompson et al. · The Lancet · 2020 · 424 citations · Full text

Public Health, Pharmacology, Pharmacotherapy +17

Persistent Decreases in Blood Plasmacytoid Dendritic Cell Number and Function Despite Effective Highly Active Antiretroviral Therapy and Increased Blood Myeloid Dendritic Cells in HIV-Infected Individuals

Jihed Chehimi, Donald E. Campbell, Livio Azzoni et al. · The Journal of Immunology · 2002 · 339 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Antonella Castagna, Franco Maggiolo, Giovanni Penco et al. · The Journal of Infectious Diseases · 2014 · 329 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Barriers and facilitators to patient retention in HIV care

Baligh R. Yehia, Leslie Stewart, Florence Momplaisir et al. · BMC Infectious Diseases · 2015 · 261 citations · Full text

Public Health, Community Health, Health Services Research +8

Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection

Mark Sulkowski, Susanna Naggie, Jacob Lalezari et al. · JAMA · 2014 · 254 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17